Press Coverage
Antoine Papiernik and Sylvain Gariel urge France to invest in vaccines
Related Deal lead
Antoine PapiernikFrance must invest much more if it wants to regain autonomy in vaccine production, or at least get sufficient access to vaccines made elsewhere, Sofinnova Partners Chairman Antoine Papiernik and Sylvain Gariel, co-founder of DNA Script, wrote in a guest editorial published in Les Echos.
Germany, the United States, Britain, Canada and Australia all have taken steps to pre-order or reserve production capacity of vaccines that may be sorely needed as the pandemic takes off again in the colder seasons.
Investment in health care has a double impact, the two leaders pointed out: mitigating the kind of drop in gross national product most countries experienced during the pandemic, and bolstering a sector with a large potential for profit.
Threats to health ignore borders, they stressed in the article published Sept. 13. France needs to act in concert with its European neighbors, diversify its commercial partners and focus on making France a truly innovative country when it comes to health care, they wrote in the leading French business daily.
Read the article in Les Echos (subscription required)
Related Articles
Pi-Cardia successfully completes enrollment in pivotal study for ShortCut™
First patients treated with TISSIUM’s Atraumatic Hernia Repair System
Moon Surgical's first-in-human trials feature in major surgical publication
HighLife launches a new Large Annulus Valve in ongoing clinical studies for patients suffering from Mitral Regurgitation
Cécile Dupont, Sofinnova MD Start Partner, selected as In Vivo Rising Leader